13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000078003
Total reported value
$170.4M
$170.4M
21 檔
202.9%
In Q3 2025, Pfizer Inc's U.S. equity holdings reached a combined market value of $170.4M, distributed across 21 disclosed stock positions.
In Q3 2025, Pfizer Inc adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including BNTX, ORIC, TRML) accounted for 202.9% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BNTX | Biontech Se-adr | Stock-Other | 37.39% | — | -54.67% | |
| 2 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 14.75% | -22.05% | — | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 13.91% | — | — | |
| 4 | ARVN | Arvinas Inc | Stock-Other | 6.73% | +1.61% | — | |
| 5 | ALLO | Allogene Therapeutics Inc | Stock-Other | 6.25% | +6.70% | — | |
| 6 | CELC | Celcuity Inc | Stock-Other | 3.95% | +4.22% | — | |
| 7 | PYXS | Pyxis Oncology Inc | Stock-Other | 3.57% | +7.57% | — | |
| 8 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.14% | +1.42% | — | |
| 9 | ✓ | Zura Bio LTD | Stock-Other | 2.94% | -5.36% | — | |
| 10 | CRBU | Caribou Biosciences Inc | Stock-Other | 2.50% | +1.13% | — | |
| 11 | BHVN | Biohaven Ltd. | Stock-Other | 1.73% | +2.93% | — | |
| 12 | CRDF | Cardiff Oncology Inc | Stock-Other | 1.14% | +0.20% | — | |
| 13 | SPRO | Spero Therapeutics Inc | Stock-Other | 1.02% | +0.82% | — | |
| 14 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.33% | +1.42% | — | |
| 15 | NXTC | Nextcure Inc | Stock-Other | 0.21% | -0.60% | — | |
| 16 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 17 | QTTB | Q32 Bio Inc | Stock-Other | 0.13% | -0.31% | EXIT | |
| 18 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.07% | — | — | |
| 19 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.04% | +0.02% | — | |
| 20 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.01% | +0.01% | — | |
| 21 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TRML | Tourmaline Bio Inc | +10.1% | — | Unchanged |
| 2 | ORIC | Oric Pharmaceuticals Inc | +8.8% | — | Unchanged |
| 3 | CELC | Celcuity Inc | +3.2% | — | Unchanged |
| 4 | PYXS | Pyxis Oncology Inc | +2.2% | — | Unchanged |
| 5 | ✓ | Zura Bio LTD | +2.2% | — | Unchanged |
| 6 | ARVN | Arvinas Inc | +1.9% | — | Unchanged |
| 7 | CRBU | Caribou Biosciences Inc | +1.6% | — | Unchanged |
| 8 | SPRO | Spero Therapeutics Inc | +0.7% | — | Unchanged |
| 9 | WVE | Wave Life Sciences Ltd. | +0.1% | — | Unchanged |
| 10 | QTTB | Q32 Bio Inc | 0% | — | Unchanged |
| 11 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | — | Unchanged |
| 12 | ANTX | An2 Therapeutics Inc | 0% | — | Unchanged |
| 13 | DNA | Ginkgo Bioworks Holdings Inc | 0% | — | Unchanged |
| 14 | SENS1GBP | Senseonics Holdings Inc | 0% | — | Unchanged |
| 15 | ALLO | Allogene Therapeutics Inc | -0.2% | — | Unchanged |
| 16 | CRDF | Cardiff Oncology Inc | -0.4% | — | Unchanged |
| 17 | EPIEUR | Essa Pharma Inc | -0.5% | — | Unchanged |
| 18 | BHVN | Biohaven Ltd. | -0.7% | — | Unchanged |
| 19 | BNTX | Biontech Se-adr | -29.1% | -54.67% | Trim |
| 20 | NXTC | Nextcure Inc | — | NEW | New buy |
| 21 | NXTCEUR | Nextcure Inc | — | EXIT | Sold out |
| 22 | BOLT1EUR | Bolt Biotherapeutics Inc | — | EXIT | Sold out |
| 23 | BOLT | Bolt Biotherapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Pfizer Inc reported a total U.S. public equity portfolio value of $170.4M across 21 disclosed positions in Q3 2025.
During Q3 2025, Pfizer Inc's top holdings by market value included BNTX (37.4%)、ORIC (14.8%)、TRML (13.9%). The largest single position, BNTX, represented 37.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
NXTC
市值: $923.8K
Top Position Liquidated / Trimmed
NXTCEUR
前期市值: $908.6K
In Q3 2025, Pfizer Inc made 5 total portfolio adjustments, initiating 2 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.